These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22943618)

  • 21. Evaluating drugs for use in children.
    Thompson RC
    FDA Consum; 1975 Mar; 9(2):14-7. PubMed ID: 10308672
    [No Abstract]   [Full Text] [Related]  

  • 22. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
    Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
    Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 24. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitating isotopic molecular labels with accelerator mass spectrometry.
    Vogel JS; Love AH
    Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.
    Lappin G; Seymour M; Young G; Higton D; Hill HM
    Bioanalysis; 2011 Feb; 3(4):393-405. PubMed ID: 21338259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
    Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
    Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could traditional mass-balance studies in the 'twilight zone' be improved by means of accelerator MS measurements?
    Svensson LD
    Bioanalysis; 2012 Aug; 4(15):1835-7. PubMed ID: 22943613
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 32. Ethical considerations in conducting pediatric research.
    Roth-Cline M; Gerson J; Bright P; Lee CS; Nelson RM
    Handb Exp Pharmacol; 2011; 205():219-44. PubMed ID: 21882114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug efficacy--double-blind studies.
    Basmajian JV; Adler P; Ord RL
    J Rehabil; 1974; 40(5):26-30. PubMed ID: 4606453
    [No Abstract]   [Full Text] [Related]  

  • 35. Pediatric drug studies. Protecting pint-sized patients.
    Nordenberg T
    FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
    [No Abstract]   [Full Text] [Related]  

  • 36. Biological and biomedical (14)C-accelerator mass spectrometry and graphitization of carbonaceous samples.
    Chung IM; Kim SH
    Analyst; 2013 Jun; 138(12):3347-55. PubMed ID: 23626987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
    Leeder JS; Kearns GL; Spielberg SP; van den Anker J
    J Clin Pharmacol; 2010 Dec; 50(12):1377-87. PubMed ID: 20150527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in pediatric pharmacology, therapeutics, and toxicology.
    Berlin CM
    Adv Pediatr; 2001; 48():439-64. PubMed ID: 11480767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
    Brown K; Tompkins EM; White IN
    Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantifying exploratory low dose compounds in humans with AMS.
    Dueker SR; Vuong le T; Lohstroh PN; Giacomo JA; Vogel JS
    Adv Drug Deliv Rev; 2011 Jun; 63(7):518-31. PubMed ID: 21047543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.